| Title: | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
| Journal: | Proceedings of the National Academy of Sciences of the United States of America |
| Published: | 10 Aug 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/35947615/ |
| DOI: | https://doi.org/10.1073/pnas.2114734119 |
Publication 10430
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large-population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations, patient samples, and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in the Genome Aggregation Database (gnomAD), with minor allele frequency (MAF) ranging from 10-5 to 10-3. Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD, and is associated with kidney failure in the 100,000 Genomes Project (odds ratio [OR] = 3.99 [1.84 to 8.98]) and the UK Biobank (OR = 4.12 [1.32 to 12.85). Compared with canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD and an intermediate reduction of urinary uromodulin levels, in line with an intermediate trafficking defect in vitro and modest induction of endoplasmic reticulum (ER) stress. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides insights into the mechanisms of ADTKD and the genetic architecture of CKD.</p>
84 Authors
- Eric Olinger
- Céline Schaeffer
- Kendrah Kidd
- Elhussein A. E. Elhassan
- Yurong Cheng
- Inès Dufour
- Guglielmo Schiano
- Holly Mabillard
- Elena Pasqualetto
- Patrick Hofmann
- Daniel G. Fuster
- Andreas D. Kistler
- Ian J. Wilson
- Stanislav Kmoch
- Laure Raymond
- Thomas Robert
- Kai-Uwe Eckardt
- Anthony J. Bleyer
- Anna Köttgen
- Peter J. Conlon
- Michael Wiesener
- John A. Sayer
- Luca Rampoldi
- Olivier Devuyst
- J. C. Ambrose
- P. Arumugam
- R. Bevers
- M. Bleda
- F. Boardman-Pretty
- C. R. Boustred
- H. Brittain
- M.A. Brown
- M. J. Caulfield
- G. C. Chan
- A. Giess
- J. N. Griffin
- A. Hamblin
- S. Henderson
- T. J. P. Hubbard
- R. Jackson
- L. J. Jones
- D. Kasperaviciute
- M. Kayikci
- A. Kousathanas
- L. Lahnstein
- A. Lakey
- S. E. A. Leigh
- I. U. S. Leong
- F. J. Lopez
- F. Maleady-Crowe
- M. McEntagart
- F. Minneci
- J. Mitchell
- L. Moutsianas
- M. Mueller
- N. Murugaesu
- A. C. Need
- P. O'Donovan
- C. A. Odhams
- C. Patch
- D. Perez-Gil
- M. B. Pereira
- J. Pullinger
- T. Rahim
- A. Rendon
- T. Rogers
- K. Savage
- K. Sawant
- R. H. Scott
- A. Siddiq
- A. Sieghart
- S. C. Smith
- A. Sosinsky
- A. Stuckey
- M. Tanguy
- A. L. Taylor Tavares
- E. R. A. Thomas
- S. R. Thompson
- A. Tucci
- M. J. Welland
- E. Williams
- K. Witkowska
- S. M. Wood
- M. Zarowiecki
1 Application
| Application ID | Title |
|---|---|
| 43879 | GWAS and genetics study of end stage renal failure and cystic kidney disease |
Enabling scientific discoveries that improve human health